The Impact of Unfair Trade Restrictions on Corporate Behavior and Financial Performance of Pharmaceutical Companies: The Dual Punishment System in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study aims to evaluate the effectiveness of the dual-punishment system by analysis of the financial performance of pharmaceutical companies before and after introduction of the dual-punishment system. This study analyzed the business performance of 136 pharmaceutical companies from 2009 to 2011. The results from paired t-tests found that sales, operating cost, and EBITDA showed significant differences in performance, and, according to the variance analysis, the five groups obtained through a hierarchical cluster analysis differed from each other in sales, operating cost, EBITDA, and research and development cost. Differences in financial performance among the groups seem to be related to the strategy for response to the regulation. The introduction of the dual-punishment system is generally acknowledged to have had positive effects on the pharmaceutical industry. However, some companies appear to be continuing kickback practices.
Abstract
This study aims to evaluate the effectiveness of the dual-punishment system by analysis of the financial performance of pharmaceutical companies before and after introduction of the dual-punishment system. This study analyzed the business performance of 136 pharmaceutical companies from 2009 to 2011. The results from paired t-tests found that sales, operating cost, and EBITDA showed significant differences in performance, and, according to the variance analysis, the five groups obtained through a hierarchical cluster analysis differed from each other in sales, operating cost, EBITDA, and research and development cost. Differences in financial performance among the groups seem to be related to the strategy for response to the regulation. The introduction of the dual-punishment system is generally acknowledged to have had positive effects on the pharmaceutical industry. However, some companies appear to be continuing kickback practices.
참고문헌 (16)
- Ministry of Health and Welfare, "OECD Health Data 2014", Ministry of Health and Welfare, ~ (2015)
- 이하영, "의약품 리베이트의 원인과 처방에 관한 신제도론적 해석", 보건행정학회지, 21(1), pp.132~157 (2011), 한국보건행정학회
- S. H. Lee, "A Study on Feasibility of Pharmaceutical Rebate Dual Punishment; Focus on the Allegations for Constitutionality", pp.2011
- 김한나, "보건의료분야 리베이트 규제의 현황 및 개선방향", 법학연구, 55(4), pp.263~288 (2014), 법학연구소
- 맹광호, "의료인과 제약회사 사이의 관계윤리", 대한의사협회지, 53(8), pp.644~646 (2010), 대한의사협회
- S. Y. Yu, "New Anti-Rebate Legislation in South Korea", Applied Health Economics and Health Policy, 11(4), pp.311~318 (2013)
- D. W. Lee, "A Study on the Effect of Company Growth before and after the Rebate Regulations in the Pharmaceutical Industry", Department of Business Administration, pp.2013
- P. M. Berthouex, "Statistics for Environmental Engineers" (1994), Lewis Publisher Press
- J. F. Hair, "Multivariate Data Analysis" (2010), Prentice Hall
- Korea Health Industry Development Institute, "KHIDI Brief, vol. 124", ~ (2013)
- 허재헌, "국내 제약회사의 의약품생산과 기업이익에 대한 탐색적 연구", 산업경제연구, 27(5), pp.1919~1950 (2014), 한국산업경제학회
- 유완진, "전략적 제휴의 진화에 따른 교섭력 및 제휴성과 변화에 관한 연구: 국내 진출 다국적 제약사 사례를 중심으로", 전략경영연구, 18(1), pp.1~30 (2015), 한국전략경영학회
- "Small Pharmaceutical Companies Still Use the Kick-back: Since There is Nothing to Lose" (2014)[URL]
- OECD, "Competition and Regulation Issues in the Pharmaceutical Industry", ~ (2000)
- D.P. Kessler, "The Effect of Pharmaceutical Price Control on the Cost and Quality of Medical Care: A Review of the Empirical Literature", ~ (2004)
- A. Wazana, "Physicians and the Pharmaceutical Industry: Is a Gift ever just a Gift?", JAMA, 283(3), pp.373~380 (2000)